Protein O-GlcNAcylation and Cardiovascular (Patho)physiology |
| |
Authors: | Susan A. Marsh Helen E. Collins John C. Chatham |
| |
Affiliation: | From the ‡Section of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Spokane, Washington 99210-1495 and ;the §Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019 |
| |
Abstract: | Our understanding of the role of protein O-GlcNAcylation in the regulation of the cardiovascular system has increased rapidly in recent years. Studies have linked increased O-GlcNAc levels to glucose toxicity and diabetic complications; conversely, acute activation of O-GlcNAcylation has been shown to be cardioprotective. However, it is also increasingly evident that O-GlcNAc turnover plays a central role in the delicate regulation of the cardiovascular system. Therefore, the goals of this minireview are to summarize our current understanding of how changes in O-GlcNAcylation influence cardiovascular pathophysiology and to highlight the evidence that O-GlcNAc cycling is critical for normal function of the cardiovascular system. |
| |
Keywords: | Calcium Cardiac Hypertrophy Cardiovascular Epigenetics O-Linked N-Acetylglucosamine (O-GlcNAc) |
|
|